CONTROL OF MAREK'S DISEASE BY THE INHIBITION OF LATENCY AND TUMOR CELL DEVELOPMENT

Abstract: A novel sequence in the genome of Marek's disease virus which is associated with the establishment of latency in MDV-infected cells, and with tumor cell development of MDV-infected cells, is described. The sequence of the 107 amino acid protein, encoded by this novel sequence, is also disclosed. Disclosed are the use of the novel sequence and the 107 amino acid protein in strategies to control Marek's disease such as by antisense therapy and vaccination, respectively.

Description: CONTROL OP MAREK'S DISEASE BY THE INHIBITION OF LATENCY AND TDMOR CELL DEVELOPMENT 1. Background of the Invention 1.1 Field of the Invention The present invention relates to a novel sequence in the rrenome of the Marek's disease virus (MDV) which is associated wit latency in MDV-infected cells and the development of ML, -infected cells into tumor cells. More particularly, this invention provides for a mechanism of protection of chickens against Marek's disease by using this novel sequence, or the protein it encodes, in the inhibit-. of the establishment of latency and tumor cell development. 1.2 Description of the Background and Related Art Marek's disease is a lymphoproliferative disease of c . ' ckens caused by MDV. MDV, a naturally occurring herpesvirus, infect-^ bursa-derived and thymus-derived lymphocytes in chi ens, and may subsequently induce a lymphoma of thymus-derived lymphocytes. Although the MDV genome is present in tumors induced in the MDV-infected chickens, these tumors are generally free of virus particles indicating that latency has been established. MDV-infected chickens may also exhibit neural involvement characterized by nerve paralysis. Since Marek's disease is contagious, the virus has become an important pathogen of chickens, particularly in an environment of large scale breeding such as in the poultry industry. Because of a lack of effective therapeutic drugs for treatment of Marek's disease, approaches to prevent the disease have focused on vaccine development. One such vaccine, described in U.S. Patent No. 4,160,024, involves a strain of MDV which is naturally nononcogenic and unattenuated. Another vaccine, disclosed in U.S. Patent No. 4,980,162, is a combined vaccine consisting of cultured cells infected with an attenuated infectious laryngotracheitis virus, and cultured cells infected with attenuated MDV or herpesvirus of turkey (HVT) . A process for preparing a plasmid vector which contains the MDV Type I Ba-mHI fragment, into which is incorporated a structural gene encoding an exogenous protein, is disclosed in U.S. Patent No. 5,171,677. Currently, Marek's disease is controlled by vaccination of embryos at 17-19 days of incubation, or one day old chicks with either HVT; serotype 2 strains of MDV; attenuated (of low pathogenicity) and/or nononcogenic strains of MDV serotype 1, or combinations thereof. However, recently vaccination breaks have been reported in chickens vaccinated with the bivalent vaccine consisting of serotype 2 MDV or HVT (R.L. Witter in Proceedings XIX World's Poultry Congress. Amsterdam, The Netherlands, 1993, 1:298-304), suggesting that new approaches are needed to control Marek's disease. Increased virulence of MDV isolates, decreased genetic resistance of chicken stocks, immunosuppression by other microbial pathogens, and poor management of vaccination procedures may be factors which have contributed to recent vaccination breaks. 2. Summary of the Invention A novel sequence, comprising an open reading frame (ORF) , has been identified in the MDV genome. RNA transcripts from this sequence have been detected in Marek's disease tumor cell lines, which have a limited number of MDV-specific transcripts. In addition, this transcript is only one of two MDV-specific transcripts in a reticuloendotheliosis virus (REV) -transformed lymphoblastoid cell line latently-infected with MDV (Pratt et al., 1992, J. Virol . 66:7239-7244). This transcript can also be detected in spleen cells obtained from chickens latently-infected with MDV (unpublished data) . Only a low rate of transcription from this sequence occurs in lytically-infected cells. The novel sequence of the present invention is non-essential for virus replication, and therefore can be used as a region for insertion and expression in MDV of other endogenous (MDV) genes or exogenous genes. Accordingly, one object of the present invention is to provide an approach to control MDV infection by interfering with the establishment of latency in MDV- infected cells and/or by interfering with the induction and development of MDV-infected cells into tumor cells. Another object of the present invention is to prevent the development of Marek's disease by inducing protective antibody and/or a cell-mediated immune response to a protein which is associated with latency and/or tumor cell development of MDV-infected cells. Another object of the present invention is to prevent the development of latency and/or tumor cells or to provide antiviral therapy by interfering with the development of the maintenance of latency by using sequences which are antisense to MDV genomic sequences whose transcription are associated with latency and/or tumor cell development in MDV-infected cells. Another object of the present invention is to provide a region in the MDV genome, wherein the region is non-essential for virus replication, into which an extra copy(s) of an endogenous (MDV) gene or exogenous gene can be inserted for expression from this recombinant viral vector. Other objects and advantages of the invention will become readily apparent from the ensuing description. 3. Brief Description of the Figures FIG . 1 is a schematic representation of the genomic structure of MDV with restriction map positions of BaιriHI- I 2 , -Q 2 , and - L regions ; and a restriction enzyme map of the BaιriHI -Q 2 region and part of the BairiHI-L fragment with locations of BamHI-L-specific cDNA clones (LI and L2) . Locations of the LI and L2 cDNA clones, the Q2L1 PCR product, and an open reading frame encoding 107 amino acids are shown as open boxes. Locations of the 1.8-kb meq transcript, and the l.Okb Bgrlll and 1.2-kb Hpall subfragments of the BairiHI-L fragment, are shown as broken lines. The location of the polyadenylation signal (ATTAAA) in LI clone is also shown. FIG. 2 represents Northern blot analysis to confirm the origins of the LI cDNA clone. Poly(A) + RNA isolated from either uninfected chicken kidney cells (CKC) (lane 1), RBlB-infected CKC (lane 2), or CU41 (lane 3) was hybridized with a probe prepared from the LI cDNA clone. Sizes of transcripts are shown in kilobases. FIG. 3 is a representation of the nucleotide sequence of the BajriHI-L-specific cDNA clone and its upstream genomic sequence obtained from analysis of the Q2L1 clone. The predicted amino acid sequence of the ORF is shown by the single-letter code above the nucleotide sequence, with amino acid numbers in parentheses. The locations of potential promoter sequences are also underlined and indicated (TAATGARAT, Oct-1, and TATA-box) . The locations of primers (#2, #3, and #4) used in reverse transcriptase PCR are also indicated. FIG. 4 is a schematic representation showing the locations of the four probes used in the RJNase protection assay. FIG. 5 is a schematic representation showing the locations of primers #2, #3, and #4 used in the reverse transcriptase-polymerase chain reaction for determining LI transcript expression. Also shown are the size of the predicted amplified fragments. FIG. 6 represents Southern blot hybridization analysis of an amplified product derived from total DNA of CU41 using primers #3 and #4 (lane 1) , and reverse- transcriptase polymerase chain amplified products derived from CU197 (lane 2) and CU210 (lane 3) , using primers 3 and 4. Lane 4 represents the result of PCR amplification of RNA prepared from CU210 (no reverse transcription) . The presence or absence of reverse transcriptase in the experimental reactions is indicated at the top of the panel. The sizes of PCR products are shown in base pairs. 4. Detailed Description of the Invention The MDV genome is a linear 180 kilobase pair double stranded molecule consisting of two unique regions: a unique short region (US) , and a unique long region (UL) . Each of the unique regions is flanked by inverted repeats: a long terminal repeat (TRL) and internal long inverted repeat (IRL) for UL, and a short internal inverted repeat (IRS) and short terminal repeat (TRS) for US (Figure 1) . Presently, the transformation process of T-cells by MDV is poorly understood. In lymphoblastoid cell lines established from Marek's disease tumors, viral gene expression is very limited whereas many viral transcripts are found in lytically infected cells (Silver et al., 1979, Virology 93:127-133) . For example, at least 66 discrete transcripts were detected by Northern blot analysis of lytically-infected chicken embryo fibroblasts (CEF) , whereas less than 8 transcripts were detected in lymphoblastoid cell lines (Schat et al., 1989, Int . J. Cancer 44: 101-109). This observation suggests that MDV oncogenicity and latency are closely related, and that the few transcripts found in Marek's disease tumor, and their corresponding gene products, may be important for the initiation and/or maintenance of latency and/or tumor cell development by MDV. Recent studies by Schat et al. (1989, supra) and Sugaya et al. (1990, J. Virol . 64:5773-5782) demonstrated that the regions actively transcribed in tumor cell lines are the US and IRS regions, which correspond to the BairiHI-H, -I 2 , -L, and -A DNA fragments according to the restriction enzyme map of MDV (Fukuchi et al., 1984, J. Virol . 51:102-109). Although it is known that the BamHI-L region of the MDV genome is actively transcribed in MDV-induced lymphoblastoid tumors and tumor cell lines, information is lacking about the identification and characterization within that region of sequence(s), and their corresponding gene products, associated with the initiation and/or maintenance of tumor cell development. Additionally, there is a lack of information as to the identification and characterization of MDV transcripts in latently-infected cells of chickens. The present invention relates to the identification and characterization of a MDV-specific cDNA clone, "LI", the sequence of which originates from the border between the BairiHI-L, and -Q 2 regions of the MDV genome, as represented in Figure 1. The cDNA clone was isolated from a cDNA library prepared from a Marek's disease lymphoblastoid cell line, MDCC-CU41 (CU41) . CU41 is a non-expression cell line which contains none or only a few cells expressing viral antigens. LI transcripts are expressed in relatively higher amounts in the Marek's disease lymphoblastoid cell line CU41 (Fig. 2, lane 3) than in lytically infected cells (Fig. 2, lane 2) . From the DNA sequence of LI, one open reading frame (LI ORF) was identified which can encode 107 amino acids (SEQ ID No. 1) . Moreover, Ll transcripts have also been detected in CU210, a T cell lymphoblastoid cell line developed by transformation with reticuloen^theliosis virus (REV) which was then latently infecte. with MDV, but not detected in the parent REV cell line free of MDV. Thus, the LI ORF, and its corresponding gene product of 107 amino acids, may be assoc with initiation and maintenance of tumor celj. development and/or establishment of latency of MDV-infected cells. Because of the lack of effective drugs to therapeutically treat chickens with Marek's disease, and with recent reports of vaccination breaks in chickens vaccinated with virus, alternative approaches to controlling Marek's disease should be considered. One embodiment of the present invention is to control the development of Marek's disease by inhibiting latency or tumor cell development in MDV-infected cells using an antisense approach. In this approach, sequences antisense to the LI ORF can be introduced into cells of " " ^ickens or chick embryos to inhibit latency and/or „ or cell development. In one variation of this embodiment, antisense to LI ORF can be injected directly into the tissue of chickens, or embryos between 17 and 21 days of incubation. In another variation of the embodiment, the LI ORF sequence can be inserted in an antisense direction in any virus vector useful as a vaccine wherein the ORF is under the control of a constitutive promoter. This recombinant viral vaccine vector can either be inoculated into embryos in ovo or into chicks directly after hatching. In yet another variation of this embodiment, sequences which can be transcribed to antisense to LI ORF are inserted in a plasmid vector. The recombinant plasmid is constructed such that in vivo transcription into antisense is regulated by either an inducible promoter or a constitutive promoter. The recombinant plasmid is then injected into embryos in ovo or into chicks directly after hatching. Another variation of this embodiment involves the development of transgenic chickens which express antisense RNA to LI ORF, wherein the transcription into antisense is under the control of an inducible promoter or a constitutive promoter. A second embodiment of the present invention relates to vaccination with the 107 amino acid gene product of the LI ORF. In one variation of this embodiment, chicks or chickens are immunized with a vaccine comprising the 107 amino acid protein which may elicit protection by inducing an immune response that would recognize cells latently-infected with MDV, or tumor cells induced by MDV infection. In another variation of this embodiment, the vaccine comprises a vector, such as a recombinant viral vector, containing the LI ORF under the control of a strong promoter so that the 107 amino acid protein is expressed. In a second variation of this embodiment, the vaccine comprises a vector such as a recombinant viral vector, containing those nucleotide sequences of this LI ORF coding for epitopes inducing humoral (approximately 15 amino acids) or cell-mediated (approximately 9 amino acids) immune responses. A third embodiment is the development of a Marek's disease virus which lacks oncogenicity. As noted in U.S. Patent No. 4,160,024 to Schat et al.. which patent is assigned to the assignee of the present invention and is incorporated herein by reference, unattenuated pathogenic strains of MDV have been unacceptable as vaccines for poultry because of their oncogenic potential. In one variation of this embodiment, the LI ORF of an unattenuated pathogenic strain of MDV can be genetically engineered not to express the 107 amino acid protein. Since the LI ORF appears non-essential for virus replication, expression of the 107 amino acid protein can be interrupted by the insertion of an exogenous sequence into the LI ORF, resulting in a recombinant MDV that is unattenuated, apathogenic, and non-oncogenic. In another variation of this embodiment, the recombinant MDV can be used as a vector in a multivalent vaccine by inserting one or more exogenous genes into the LI ORF. An exogenous gene would encode protein which acts as an effective antigen in inducing a protective immune response against its corresponding organism of origin. Thus, the recombinant MDV could serve as a combined vaccine against Marek's disease and against other diseases of poultry. In another variation of this embodiment, one or more copies of an endogenous gene, whose gene product is an antigen capable of eliciting a protective ir.-mine response, can be inserted within the LI ORF to increase antigen expression for vaccine purposes. For example, glycoprotein B (gB) is a major glycoprotein produced by MDV, which when inoculated into chickens results in the production of neutralizing antibody. Multiple copies of the gene encoding gB can be inserted in the LI ORF to make a more effective recombinant vaccine against Marek's disease. EXAMPLE 1 Isolation and Characterization of the LI ORF The LI ORF is a sequence derived from the sequence of an MDV-specific cDNA clone, LI, obtained through screening of the CU41 cDNA library with the gel-purified BamHI-L fragment as a probe. CU41, a Marek's disease lymphoblastoid cell line established from a RBIB-induced tumor (MDV strain RBIB is a very highly oncogenic strain described previously by Schat et al., 1982, Avian Pathol . 11:593-605), is a non-expression cell line which contains none or only a few cells expressing viral antigens (Calnek et al., 1981, Infect. I mun. 34:483- 491) . CU41 was selected for making the cDNA library because only six MDV-specific transcripts, including a 0.6-kb BamHI-L transcript, were detected in this cell line (Schat et al. , 1989, supra) . For the isolation of cDNA clone LI, a cDNA library was prepared from the poly(A) + RNA obtained from CU41 cells. The library was screened by plaque hybridization with a 32 P-labeled MDV (strain GA) BamHI-L fragment, and the hybridizing phages were plaque-purified. Subsequent in vivo excision and rescue of pBluescript (SK)™ carrying cDNA inserts were performed. Southern blot analysis was performed to determine the approximate map position of the cDNA clone LI. The BamHI-L fragment was digested by Bgrlll, fractionated on a 1.2% agarose gel, and transferred to a nylon hybridization membrane. In a separate restriction, the BamHI-L fragment was digested with Hpall, fractionated on a 1.2% agarose gel, and transferred to a nylon membrane. 32 P-labeled probes were prepared by using gel- purified cDNA inserts as templates, and hybridizations with the membranes were performed. As shown in Figure 1, from Southern blot analysis it was determined that the LI cDNA clone hybridized with a 1.0 kb B≤rlll subfragment and a 1.2 kb Hpall subfragment of the BamHI-L fragment. By aligning the subfragments with the restriction map of the BamHI-L fragment, the exact location of the subfragments could be determined, as shown in Figure 1. The 3' end of the LI clone was localized at 221 bases to the right of the left Ba HI site of the BamHI-L fragment. In order to characterize the transcripts coded for by LI, a radiolabeled probe was prepared from the LI cDNA clone, and used for Northern blot analysis. In this experiment, total cellular RNA was isolated from uninfected chicken kidney cells (CKC) , RBIB-infected CKCs, and CU41 using the method of Chomczynski et al. (1987, Anal . Biochem. 162:156-159). Poly(A) + RNA, purified from the total cellular RNA preparations, were used in the Northern blot analysis. For Northern blotting, 2 μg of each of the poly(A) + RNA fractions were fractionated by electrophoresis in 1.2 % agarose gel containing 2.2 M formaldehyde (15), and blotted onto nylon membranes. RNA blots were prehybridized for 3 hours at 42° C in 50% formamide, 5X SSPE, 5X Denhardt's solution, 0.1% SDS and 100 μg/ml denatured salmon sperm DNA. Hybridization was performed for 18-20 hours at 42°C in the same solution with addition of the radiolabeled LI probe. After hybridization, the membranes were washed twice with 2X SSPE containing 0.5% SDS at 65°C for 60 minutes. The hybridized filters were autoradiographed at -80°C with Kodak X-Omat AR film and intensifying screens. The results of the Northern blot analysis of the poly(A) + RNA fractions from the uninfected CKC, the RBIB-infected CKC, and CU41, are shown in Figure 2. Three LI-specific transcripts of 2.5 kb, 0.8 kb, and 0.6 kb were detected. The amounts of these transcripts appear to be relatively more abundant in the RNA sample of CU41 than in that of RBIB-infected CKC. The LI probe did not hybridize with the RNA sample from uninfected CKC. Previous studies of MDV-transcripts coded for by the BamHI-L region in CU41 indicated the existence of a 0.6 kb transcript (Schat et al., 1989, supra) . The LI cDNA clone (300 bp) was subcloned into pBluescript KS(+)™ and sequenced using the dideoxy- sequencing method. The sequence of the LI cDNA clone is shown in Figure 3. In addition, a 1070-bp Clal-BamHI fragment derived from PCR amplification, corresponding to the upstream region of the LI cDNA clone, was also sequenced. The polymerase chain reactions, carried out to amplify a genomic fragment in the BamHI-Q2 region, were performed using a standard procedure. The two primers used, #1 (5' -CAACATAAAGGAAAGGG-3' ) and #2 (5' -CGTAATGGATCCCGTCC-3') , were designed from sequence data of the EcoRI-Q fragment (Jones et al., 1992, supra) and the LI clone, respectively. The locations of the primers are shown in Figure 3. The amplified fragment, termed Q2L1, was then digested with both Clal and BamHI, and cloned into pBluescript KS(+)™, and used for DNA sequencing. The nucleotide sequences of LI and Q2L1 were aligned, as represented in Figure 3. Analysis of the sequences resulted in identification of one ORF which can encode a predicted polypeptide of 107 amino acids (Figure 3, SEQ ID No. 1) . The calculated molecular weight of the polypeptide is 12,385 dalton. The potential translation initiation site (ATG) of the ORF was located at positions 725-727. A 237-base 3' untranslated sequence was present in the cDNA, and a putative poly(A) signal, ATTAAA, was present at positions 1262- 1267. DNA sequence analysis of the 5' upstream region of the cDNA clones resulted in identification of two potential TATA box-like sequences. These are TATAATT at positions 444-450, and TAATATATA at positions 665-673, from which the length of the predicted transcripts are approximately 0.8 and 0.6 kb without poly(A) tails respectively. Both of these two TATA elements are located downstream of the polyadenylation signal (AATAAG, positions 402407) for the 1.8-kb meg transcript. Furthermore, some potential transcriptional regulatory sequences were also identified in the region adjacent to the LI ORF. An Oct-1 binding motif (ATGCAAAT) was found at positions 648-655. In addition, three copies of similar sequences, ATGCACAGA (positions 656-664, and 679-687), and ATGCACCGA (positions 679-687), were also found near that motif. To map the 5' end(s) of the LI transcripts, RNase protection assays were performed with four different probes which covered the predicted LI transcription unit and its upstream region, as shown in Figure 4. Several subclones were obtained by cloning restriction enzyme-digested cDNA and amplified products from polymerase chain reactions into pBluescript (KS)™. Using these subclones as templates, 32 P-labeled antisense RNA probes were synthesized with either T3 or T7 RNA polymerase. Each of these probes (3 X 10 5 cpm) was annealed to a total RNA sample (50 μg) prepared from either CU41, CU197 (a reticuloendotheliosis-transformed T lymphoblastoid cell line) , RBIB-infected CKC, or uninfected CKC for 18 hours at 42° C, and then digested with RNase. Protected fragments were resolved on 6% polyacrylamide-8M urea sequencing gels and detected by autoradiography. In this determination of 5' end of the 0.6-kb LI transcript, some undigested probes were present due to incomplete digestion by RNase after hybridization. However, it was clear from this determination that these four probes specifically hybridized with RNAs from CU41 and RBIB-infected CKC, but not with those from uninfected CKC and CU197. The 514 base Sall-Hinfl region is covered by probes 2, 3, and 4. This region, which corresponds to the LI ORF and 3' noncoding region of the LI cDNA, was fully protected when hybridized with the RNA sample from either CU41, or RBIB-infected CKC. In addition to a fully protected 193-base fragment, smaller fragments of two different sizes (115, and 42 bases) were detected when the probe l, corresponding to the Mscl- Sall fragment, was hybridized with the RNA sample from either CU41, or RBIB-infected CKC. According to DNA sequence data (Figure 3) , a TATA box-like sequence was localized 55 bases upstream of the -Sail site, and the predicted length of an unspliced transcript from this TATA box is approximately 600 bases; this agrees with the result of Northern blot analysis. The Northern blot analysis for the RNase protection assays confirmed the observation in the Northern blot analysis used to characterize the transcripts coded for by LI cDNA, in that the amount of the LI transcripts were higher in CU41 than in lytically infected CKC. Reverse transcription-polymerase chain reaction was done to determine whether the LI transcript is expressed in CU41, an RBIB-transformed non-expression lymphoblastoid cell line, and CU210, a reticulo- endothelial virus-transformed cell line latently infected with MDV (Pratt et al., 1992, J " . Virol . 66: 7239-7244) . CU197, a reticuloendotheliosis-transformed T lymphoblastoid cell line, was used as a control for this determination. The reverse transcriptase-polymerase chain reaction was carried out using a commercially available kit and by following the protocol provided by the manufacturer. After treatment with DNase, 1 μg of total RNAs prepared from CU41, CU197 and CU210 were reverse-transcribed with the primer #2 (as schematically represented in Figure 5. Primers used for subsequent PCR amplification of the cDNA were primer #3 (5'-AGTAATCTGCGTTAAGTCGTTA-3') , and primer #4 (5'- GTAAACAATGCCACATCGTAGA-3' ) . The amplified fragments were resolved in 2.0% agarose gel, and analyzed by Southern blotting. Amplification with primers 3 and 4 resulted in an amplified 225 bp fragment located within the LI ORF from CU41 (Figure 6, lane 1) and CU210 (Figure 6, lane 3), but not from the control cell line CU197 (Figure 6, lane 2) . An additional 272-bp fragment was also amplified in the same reaction as noted in Figure 6, lane 3. Since not only the 225 bp band but also 272-bp were hybridized with the LI probe, it was concluded that the 272-bp fragment was generated due to the amplification between the primer #3, and primer #2 which was used for reverse transcription and coexisted during this reaction. No DNA was amplified in RNA from CU197, and RNA from CU210 in the absence of reverse transcriptase. EXAMPLE 2 Inhibition of latency and/or tumor cell development in MDV-infected cells This embodiment of the present invention is to control the development of Marek's disease by inhibiting latency and/or tumor cell development in MDV-infected cells using an antisense approach. Viral latency and transformation are known to be intimately related in MDV. It has been reported that a 0.6-kb BairiHI-L-specific transcript (one of only two MDV- specific transcripts detected from CU210) , is expressed in a relatively high amount in CU210, an REV-transformed cell line latently infected with MDV (Pratt et al., 1992, supra) . The data presented in Example 1 clearly show that CU210 expresses the origin of the LI and cDNA clone, and the size of the LI transcript is 0.6-kb. Thus, the LI transcript appears to be associated with MDV latency in tumor cells. Further support for this association are the findings, presented in Example 1, that a) LI transcripts are more abundant (high level of transcription) in the MDV-transformed cell line CU41 than in lytically infected cells (low level of transcription) ; b) a high level of LI transcripts are also detected in cells latently-infected with MDV, as evidenced by analysis of CU210; and as illustrated by the following experiment where LI transcripts have been detected by Northern blot analysis of RNA from chicken spleen cells latently-infected with MDV. Using methods and materials according to Example 1, chickens lytically infected, and chickens latently infected, with MDV were analyzed for the presence of Ll transcripts in their spleen cells. Nsa chickens were infected at 3 weeks of age with MDV strain GA-5. At various days post infection (DPI) , birds were analyzed by harvesting spleen cells, isolating RNA samples, and treating the RNA with RNAse-free DNAse to remove contaminating DNA. Reverse transcriptase polymerase chain reactions (RT-PCR) were performed using different sets of primers to amplify cDNA from different immediate early gene transcripts comprising LI, meq, PP 48 , Hf, and ICP 4 . Table 1 shows that LI transcripts can be detected in lytically-infected chickens (5-9 DPI) , and in latently-infected chickens (12-14 DPI) . Table 1 Transcription From Immediate Early Genes In The Infection Process As Detected By RT-PCR Number of Positives DPI # of virus LI meq PP 48 Hf ICP 4 birds 5 5 + 2/5 2/5 5/5 5/5 2/5 2 - 0/2 0/2 1/2 * 0/2 0/2 9 5 + 5/5 5/5 5/5 5/5 4/5 1 - 0/1 0/1 1/1 * 0/1 0/1 12 5 + 4/5 5/5 5/5 5/5 4/5 1 - 0/1 0/1 0/1 0/1 0/1 14 5 + 2/5 4/5 4/5 4/5 1/5 1 - 0/1 0/1 0/1 0/1 0/1 + control (RNA of CU41) + + + + + - control - - - - - probably contamination of RNA or non-specific reaction Table 2 is the same protocol of RT-PCR except that reverse transcriptase was omitted in the experimental design to confirm that the results in Table l represents amplified cDNA rather than amplified DNA from contaminating DNA still present in the sample. Expression from late genes are currently under investigation. Table 2 PCR Control Experiment (without RT) In Analyzing Transcription From Immediate Early Genes In The Infection Process Number of Positives DPI # of virus LI meq PP8 Hf ICP 4 birds 5 5 + 0/5 0/5 0/5 0/5 0/5 2 - 0/2 0/2 0/2 0/2 0/2 9 5 + 0/5 0/5 0/5 0/5 0/5 1 - 0/1 0/1 0/1 0/1 0/1 12 5 + 0/5 0/5 0/5 0/5 0/5 1 - 0/1 0/1 0/1 0/1 0/1 14 5 + 0/5 0/5 0/5 0/5 0/5 1 - 0/1 0/1 0/1 0/1 0/1 + control (DNA of CU41) + + + + + * - control - - - - an additional negative control for LI included RNA from CU41 In this approach to inhibiting latency and/or tumor cell development in MDV-infected cells, sequences antisense to the LI ORF, or alternatively to LI ORF transcripts, can be introduced into cells of chickens or chick -imbryos. Using the methods according to Example 1, or other methods known in the art such as oligo¬ nucleotide synthesis, sequences can be produced that are antisense to the LI ORF, or alternatively to LI ORF transcripts. An antisense sequence is defined as a complementary strand to the target strand or sequence (i.e. wherein the nucleotide sequence is inverted in order to its complementary bases) such that the antisense sequence can hybridize to the target sequence under conditions known to those skilled in the art. In this embodiment, the antisense sequence may be a nucleotide sequence of 10 bp or greater which hybridizes to the LI ORF, or to its corresponding upstream sequences involved in the regulation and initiation of transcription, wherein hybridization blocks transcription from the LI ORF. Such sequences are readily apparent to those skilled in the art from the sequence of the LI ORF and its corresponding upstream regulatory regions disclosed in Figure 3, and SEQ ID No. 1. Similarly, antisense RNA can be produced to effect sequence-specific inhibition of translation from the LI ORF transcripts. In one variation of this embodiment, antisense to LI ORF, or alternatively to LI ORF transcripts, can be injected directly into the tissue of chickens, or embryos between 17 and 21 days of incubation. A requirement of this variation is that the antisense must be capable of penetrating the tissue cell membranes so as to effect hybridization to its LI-specific target sequence in an MDV-infected cell and consequently inhibit viral function. In this respect, antisense oligonucleotides, such as phosphodiester oligos, have been demonstrated to be internalized by cells and subsequently exhibit inhibition of viral function (Stein et al., 1993, Science 261:1004-1012). In another variation of this embodiment, using methods known to those skilled in the art, the LI ORF sequence can be inserted in an antisense direction into any virus vector useful as a vaccine, wherein transcription of antisense RNA from the ORF is under the control of a constitutive promoter. This recombinant viral vaccine vector can either be inoculated into embryos in ovo or into chicks directly after hatching. In yet another variation of this embodiment, using methods known to those skilled in the art, sequences which can be transcribed to antisense to LI ORF transcripts are inserted into a plasmid vector. The plasmid vector is constructed to have an origin of replication such as from SV40, and a eukaryotic promoter or transcriptional control elements such as an MDV promoter or other viral transcriptional control elements known the art. The recombinant plasmid is constructed such that in vivo transcription into antisense is regulated by either an inducible promoter or a constitutive promoter. The recombinant plasmid is then injected into embryos in ovo or into chicks directly after hatching. Direct gene transfer into animals resulting in expression of the exogenous gene in vascular endothelial cells, as well as the tissue of the major organs, has been demonstrated by techniques in the art such as by injecting intravenously an expression plasmid:cationic liposome complex (Zhu et al., 1993, Science 261:209-211) . Other effective methods for delivering vector DNA into a target cell are known in the art. In one example, purified recombinant plasmid DNA containing viral genes has been used to inoculate (whether parentally, mucosally, or via gene-gun immunization) chickens to induce a protective immune response (Fynan et al., 1993, Proc. Natl . Acad. Sci . USA 90:11478-11482). In another example, cells removed from the chick or embryo can be transfected or electroporated by standard procedures known in the art, resulting in the introduction of the vector DNA into the target cell. Cells containing the vector DNA may be selected from those lacking the vector DNA by incorporating a selection marker into the vector . ich as the neo gene, and growing the cells in the corresponding selection media such as in the presence of G418. Selected cells, containing the recombinant expression vector for expressing antisense to LI ORF transcripts, may then be reintroduced into the chick or embryo. Antisense RNA transcribed from such vectors can hybridize to LI ORF transcripts produced when the cells are infected by MDV, and thus are available to inhibit latency, and/or development of the infected cells into tumors. Another variation of this embodiment involves the development of transgenic chickens which express antisense RNA to LI ORF transcripts, wherein the transcription into antisense is under the control of an inducible promoter or a constitutive promoter. Methods known in the art for producing a transgenic chicken include the introduction of the genetic material into the chicken germ line cells by microinjection, viral infection, or embryonic stem cell transfer. Introduction of the genetic material, such as a sequence which can be transcribed into antisense to LI, results in lineages that carry the integrated genetic material. Detection of transgenics can be accomplished by isolating tissue cells and examining the isolated cells for integration of the transgene by Southern blot analysis, or for expression of the antisense RNA to the LI ORF by Northern blot analysis. EXAMPLE 3 This embodiment of the present invention relates to vaccination with the 107 amino acid (aa) gene product of the LI ORF. In one variation of this embodiment, chicks or chickens are immunized with a vaccine comprising the 107 aa protein which may elicit protection by inducing an immune response that would recognize cells latently- infected with MDV, or tumor cells induced by MDV infection. The 107 aa protein from infected cells, or recombinant protein produced from an expression vector system, can be purified with methods known in the art including detergent extraction and/or immunoaffinity chromatography. Immunopurification of the protein from an expression vector system may be accomplished using methods known in the art for immunoaffinity chromatography including use of 107 aa protein-specific monoclonal antibodies linked to a chromatographic matrix to form an affinity matrix. A protein preparation is then incubated with the affinity matrix allowing the antibodies to bind to the 107 aa protein. The affinity matrix is then washed to remove unbound components and the 107 aa protein is then eluted from the affinity matrix resulting in a purified preparation of 107 aa protein. The purified 107 aa protein may be chemically or enzymatically cleaved into peptides, or alternatively, peptides may be synthesized using the deduced amino acid sequence from the LI ORF (SEQ ID No. 1) as a reference. Peptides derived from the 107 aa protein may also be useful in a vaccine preparation. A portion of the 107 aa protein has been purified using an expression system wherein the plasmid expression vector (pGEX2T) directs the synthesis of foreign polypeptides in E. coli as a fusion protein with glutathione-S-transferase (GST) , a 26 kilodalton protein from Schistosoma japonicum. In this mode of the embodiment, the LI ORF was amplified by the polymerase chain reaction using oligonucleotides that amplify the Mscl- BamHI fragment (see restriction map in Fig. l) from CU41 genomic DNA resulting in a 609 bp fragment termed ECQ. The amplified product from the reaction was purified by phenol/chloroform extractions, and by glass matrix chromatography and elution. pBluescript- KS™ was digested with Spel , and purified ECQ was digested with Sspl and BamHI. The Spel-digested pBluescript- KS™ was subsequently blunt-ended, digested with BamHI, and then purified. The resultant pBluescript- KS™ fragment was ligated with the Sspl- BamHI ECQ fragment in forming pBS- ECQ-SSB. The insert containing a portion of the LI ORF was cloned into pGEX2T by digesting pGEX2T and pBS-ECQ- SSB with BspEI and Eco-RI. The resulting pGEX2T fragment (5 kb) and the fragment containing a portion of the LI ORF (222 bp) were then purified, and ligated. To express epitopes of the 107 aa protein, a clone transformed with the resultant plasmid was grown in 3 ml of LB broth with ampicillin at 37°C overnight. Then, the culture was diluted x 100 in LB broth with ampicillin and incubated for 2 hours at 37°C with shaking. IPTG was added to 2mM and the culture was incubated for an additional 3 hours. Cells were harvested by centrifugation and analyzed for the expression of a portion of the 107 aa protein by SDS-PAGE using 10% acrylamide gels. The fusion protein containing a portion of the 107 aa protein was cut from the gels, eluted from the gel slices, dialyzed, and the dialysate was concentrated. Three to four week old chickens have been immunized with the purified fusion protein to generate 107 aa-specific antisera. A construct containing the complete LI ORF inserted into pGEX2T has been constructed using similar techniques. Note that with either construct, purified fusion protein may be obtained by the use of preswelled glutathione-agarose beads, and by following the directions of the manufacturer. An expression vector system, useful for vaccine development, comprises a host containing a recombinant vector which expresses the 107 aa protein. Such hosts include, but are not limited to, bacterial transformants, yeast transformants, filamentous fungal transformants, and cultured cells that have been either infected or transfected with a vector which encodes the 107 aa protein. The protein or peptide immunogen is included in a vaccine formulation in therapeutically effective amounts to induce an immune response. The vaccine may further comprise a physiological carrier such as a solution, a polymer or liposomes; and an adjuvant, or a combination thereof. Another mode of this embodiment provides for either a live recombinant viral vaccine, or an inactivated recombinant viral vaccine, comprising a viral vector containing the LI ORF under the control of a strong promoter so that the 107 amino acid protein is expressed. Examples of such viral vectors known in the art include a live attenuated infectious laryngotracheitis virus, attenuated chick fowlpox virus, or attenuated herpes virus of turkey; i.e. an infectious virus that can be engineered to express vaccine antigens derived from other organisms. The recombinant live virus, which is attenuated or otherwise treated so that it does not cause disease by itself, is used to immunize chicks or chickens. Subsequent replication of the recombinant virus within the host provides a continual stimulation of the immune system with vaccine antigens such as the 107 aa protein, thereby providing long- lasting immunity. To illustrate this mode of the embodiment, using molecular biological techniques such as those illustrated in Example 1, the LI ORF may be inserted into the viral vector genomic DNA at a site which allows for expression of the 107 aa protein epitopes but does not negatively affect the growth or replication of the viral vector. The resultant recombinant virus can be used as the immunogen in a vaccine formulation. The same methods can be used to construct an inactivated recombinant viral vaccine formulation except that the recombinant virus is inactivated, such as by chemical means known in the art, prior to use as an immunogen. EXAMPLE 4 This embodiment of the present invention provides for the development of a Marek's disease virus which lacks oncogenicity. As noted in U.S. Patent No. 4,160,024 to Schat et al.. unattenuated pathogenic strains of MDV have been unacceptable as vaccines for poultry because of their oncogenic potential. In one mode of this embodiment, the LI ORF of an unattenuated pathogenic strain of MDV can be genetically engineered not to express the 107 amino acid protein by inserting an exogenous sequence into the LI ORF to interrupt its expression. For example, a lacZ ORF under the control of its own promoter was inserted into a LI ORF-containing plasmid as follows. Plasmid pBSI2Q, containing the Clal- EcoRl fragment of the LI ORF and a region of 730 bp upstream from the start codon (see Figure 3) was digested with Ecα l and BamHI, and gel purified. pBS2.1, containing the 101 bp fragment of the Q2 region of the BamHI library of MDV DNA, as well as the remainder of the LI ORF, was restricted with EcoRl and BamHI. The gel-purified 101 bp EcoRl - BamHI fragment was ligated to the Eco-Rl-BamHI digested pBSI2Q in forming pBSQ2LI. pBSQ2LI was digested with EcoRl and N el to remove most of the LI ORF, and the remainder of the plasmid was blunt-ended. A lacZ cassette containing the SV40 promoter, obtained from pCHHO and subsequently blunt-ended, was blunt-end ligated to the -EcoRl -Ndel fragment of pBSQ2LI. The orientation of the lacZ cassette in the resulting plasmid was verified by restriction enzyme analysis, and two independent clones were analyzed for transient expression of LacZ in chicken embryo fibroblasts. This latter construct lacked an upstream MDV flanking sequence; therefore, a 2.1 kb BamHl-Xbal fragment from pBS.L was inserted directly behind the MDV-derived BamHI site. This 2.1 kb fragment contains a 1 kb Bgrlll subfragment and a 0.8 BamHI-XhoI subfragment located directly upstream from the BamHI-Q2 fragment. The final resulting plasmid, pBSLlLacZ contained the lacZ in forward orientation inserted in the remaining sequence of the LI ORF. Total MDV DΝA was purified from the CV1988 strain of MDV. MDV fragments containing lacZ were prepared by digesting pBSLlLacZ with Apal and -Xbal. Total MDV DΝA (4 μg) , and the Apal and -Xlbal of pBSLlLacZ (different dilutions) , were used to co-transfect chicken embryo fibroblasts (CEF) using the calcium precipitation method. Cultures were stained with 0.2 mg/ l Bluo-Gal™ at 5 days post transfection; and blue-staining plaques were removed from the monolayer, trypsinized, and co- cultured with secondary CEF. Recombinant viruses were plaque-purified by repeating selection of lacZ- expressing plaques (usually 4-6 times) until stable recombinants were isolated. Chicken embryo fibroblasts have been lytically-infected with the plaque-purified lacZ-expressing recombinant MDV, thus demonstrating that the LI ORF is non-essential for virus replication. By inserting an exogenous sequence into the LI ORF, thereby interrupting transcription from the LI ORF, a recombinant MDV that is unattenuated, pathogenic, and non-oncogenic may be developed which would be useful in a vaccine against MDV. In another mode of this embodiment, the recombinant MDV can be used as a vector in a multivalent vaccine by inserting one or more exogenous genes, under the control of its own promoter or a MDV promoter, into the Ll ORF. Note that for this and related embodiments, the Ll ORF is present in the long inverted repeat region (IRL, Fig. 1) , and therefore is also present in the long terminal repeat region (TRL, Fig. 1) . Thus, since the Ll ORF is in a repeat region which is duplicated in the viral genome, insertion into the Ll ORF for gene expression may result in twice the amount of gene expression, as compared to if only a single insertion site were used. As demonstrated above, an exogenous protein can be inserted into the Ll ORF, and the resultant recombinant virus is still capable of latently-infecting chicken cells. Desirably, one or more exogenous gene(s) inserted into the Ll ORF would encode protein which acts as an effective antigen in inducing a protective immune response against its corresponding organism of origin. Thus, the recombinant MDV could serve as a combined vaccine against Marek's disease and against other diseases of poultry. Examples of such antigens useful in a combined vaccine, and their corresponding pathogen and disease caused, are known in the art of veterinary medicine. For example, genes encoding antigens of infectious laryngotracheitis virus causing infectious laryngotracheitis, can be inserted into the Ll ORF for expression. In another example, one or more copies of the gene encoding the viral hemagglutinin glycoprotein of the chicken fowlpox virus causing fowlpox, can be inserted into the Ll ORF for expression. In yet another example, one or more copies of either or both of the gene encoding the HN antigen or the gene encoding the F antigen of Newcastle disease virus causing Newcastle disease, can be inserted in the Ll ORF for expression. Recombinant expression of Newcastle disease viral antigens in HVT has been described previously (Morgan et al. in Proceedings XIX World's Poultry Congress. Amsterdam, The Netherlands, 1993) . In another mode of this embodiment, one or more copies of an endogenous (MDV) gene, whose gene product is an antigen capable of eliciting a protective immune response, can be inserted within the Ll ORF to increase antigen expression for vaccine purposes. For example, glycoprotein B (gB) is a major glycoprotein produced by MDV, which when inoculated into chickens results in the production of neutralizing antibody (Nazerian et al., 1992, J. Virol . 66:1409-1413). Multiple copies of the gene encoding gB can be inserted in the Ll ORF under the control of a MDV promoter to make a more effective recombinant vaccine against Marek's disease. One or more of the other major viral glycoproteins of MDV, such as gA, may induce a protective immune response consisting of either cellular immunity, or humoral immunity. It should be understood that while the invention has been described in detail herein, the examples were for illustrative purposes only. Other modifications of the embodiments of the present invention that are obvious to those skilled in the art of molecular biology, veterinary medicine, and related disciplines are intended to be within the scope of the appended claims. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANTS: Karel A. Schat, Kazuhiko Ohashi, and Priscilla H. O'Connell (ii) TITLE OF INVENTION: Control Of Marek's Disease By The Inhibition Of Latency And Tumor Cell Development (iii) NUMBER OF SEQUENCES: 1 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear (B) STREET: 1800 One M&T Plaza (C) CITY: Buffalo (D) STATE: New York (E) COUNTRY: United States (F) ZIP: 14203-2391 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Diskette, 3.5 inch, 720 Kb storage (B) COMPUTER: IBM Compatible (C) OPERATING SYSTEM: MS-DOS/ Microsoft Windows 3.1 (D) SOFTWARE: Wordperfect for Windows 5.1 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: U.S. Serial No. 08/180,051 (B) FILING DATE: January 11, 1994 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Nelson, M. Bud (B) REGISTRATION NUMBER: 35,300 (C) REFERENCE DOCKET NUMBER: 18617.0005 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (716) 856-4000 (B) TELEFAX: (716) 849-0349 (2) INFORMATION FOR SEQ ID NO. 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1285 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single-stranded (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: yes (iv) IMMEDIATE SOURCE: (A) LIBRARY: cDNA (B) CLONE: clone Ll (v) ORIGINAL SOURCE: (A) ORGANISM: Marek's Disease Virus (B) STRAIN: MDCC-CU41 (C) CELL TYPE: virus (iii) FEATURE: (A) LOCATION: Ll open reading frame, 725-1045 (B) IDENTIFICATION METHOD: by experiment (C) OTHER INFORMATION: (iv) SEQUENCE DESCRIPTION: SEQ ID NO. 1: ATCGATTTAC TGACATAAAA AAATCCTCTG GGGTAACAAA TTTTCCTTAC 50 CGTGTAGCTT AGACTCGGAA GAACTATTTT GAGTTACATG GTCAGGGGAT 100 TTGTTGGCTC CAGGAGTTCC GAAGTATTAG ATAAACTTAG CTATGTGGAA 150 AACTTCTGGG GCAACATCCC TCGGCCCCAG ACTGCTTAAA TGGCAAATTC 200 ■ TCGTTCTATA CAGAACGGTT GGGGAAGGGG GGGGGGGTAT GGAGTATTAT 250 TCGGGATATG GCTTCTATGA AGCTGCGGTA AGTTTTCCAG GCTCAAAAAC 300 TATGCCTGGC TGTTTTTTTT TTTTTTTTTT TTAGAAGGGA TATGGACATC 350 GCACATTAAG GAATATTAAA GATAACAGGA TGGACATTCG GATGTAAAAG 400 GAATAAGCGA AACCTTTAGC AGATGTGAGT TAATGCAGTC TCGTATAATT 450 CGGTGGTGCT GATTAGGTTA TCGTAAGGAA CAACACGATT GATCTCTCAT 500 CCGCGTCCCA GCAATCAGGC CTATGTCCCT CTCCTGTGGC CAGCTCACTG 550 GCTGTGCACT GTGCGATTCT AAGTGCTACA GTCGTGAGCA GATCAATGGA 600 TCGGGGCTCG CGCAACACTA CTGTAATTAA ATATTCGTTT ATGAATTATG 650 CAAATATGCA CAGATAATAT ATACAGGGAT GCACAGACAT ACTCCTATGC 700 ACCGATACAC AGGCACATAG GCAG ATG TCG ACA TTA ACG AAT ATA 745 Met Ser Thr Leu Thr Asn lie 1 5 CAG GCA CGG ACC TCC AGG AAC ATA TGG AAA ATA CCT CAT CGC 787 Gin Ala Arg Thr Ser Arg Asn lie Trp Lys lie Pro His Arg 10 15 20 AGA GAC GCT TAT GCA GGA GTA ATC TGC GTT AAG TCG TTA CTG 82 Arg Asp Ala Tyr Ala Gly Val lie Cys Val Lys Ser Leu Leu 25 30 35 GAT TGT AAC GGC TAT CCG GAG ACT CTC TTC CCC TTT TGC TTG 871 Asp Cys Asn Gly Tyr Pro Glu Thr Leu Phe Pro Phe Cys Leu 40 45 TTC ACT GTG CGG CAT TAT TAC ATT TAC ACC GGT AAT GCT GCG 913 Phe Thr Val Arg His Tyr Tyr lie Tyr Thr Gly Asn Ala Ala 50 55 60 CAT GAA AGA GCG AAC GGA ACG AGG CTC GTA CGA CAT TAC AAG 955 His Glu Arg Ala Asn Gly Thr Arg Leu Val Arg His Tyr Lys 65 70 75 AAT AGT TTG AAT TCT CGG GAT AAT CTC CCG ATG GCC TCC CCC 997 Asn Ser Leu Asn Ser Arg Asp Asn Leu Pro Met Ala Ser Pro 80 85 90 TTA TGC TTT CTC TAC GAT GTG GCA TTG TTT ACG CGG CAG TGC 1039 Leu Cys Phe Leu Tyr Asp Val Ala Leu Phe Thr Arg Gin Cys 95 100 105 CAC GTG TGAGGGGACG ATCGGGACGG GATCCATTAC GTAAAATTTA 1085 His Val 107 GATCTTTTGT AGAAATTCAA TTCCCTTCCC CTTTTACTTT GTTTGATGTG 1135 TGCCACTGTT GTACCGATAG TGCCGCGCGT GAAAGAGTGA ACGGGAAGGG 1185 CTTACGTAAA GAACTGTCGG TGCCGGTACG GGGGAAGCTG TAACGCATTT 1235 CGAGTCTTGA TAAAGCAGAG CATGAAATTA AATCGTATCG CTCCTAAAAA 1285

Claims: We claim: 1. A Marek's disease (MDV) virus nucleotide sequence, and the polypeptide it encodes, which is associated with the establishment of latency in MDV-infected cells and tumor cell development of MDV-infected cells, said sequence and polypeptide consisting essentially of SEQ ID No. 1. 2. A method of inhibiting the establishment of latency in MDV-infected cells and tumor cell development of MDV- infected cells by inhibiting in the infection process transcription from the MDV Ll open reading frame (ORF) , said method comprising: Introduction into chicken cells of DNA which is antisense to a nucleic acid sequence within SEQ ID No. 1, wherein the sequence is essential for the transcription of the Ll ORF. 3. The method of claim 2, wherein said antisense DNA is synthesized. 4. A method of inhibiting the establishment of latency in MDV-infected cells and tumor cell development of MDV- infected cells by inhibiting in the infection process translation from the MDV Ll ORF transcript, said method comprising: Introduction into chicken cells of RNA which is antisense to all or a portion of a nucleic acid sequence transcribed from SEQ ID No. 1, wherein the sequence comprises the Ll ORF transcript. 5. The method of claim 4, wherein the antisense RNA is synthesized. 6. The method of claim 4, wherein said antisense RNA is transcribed from a recombinant vector containing the Ll ORF sequence in an antisense direction. 7. The method of claim 6, wherein said vector is a viral vector and transcription into antisense RNA is under the control of a constitutive promoter. 8. The method of claim 6, wherein said vector is a plasmid and transcription into antisense RNA is regulated by a promoter selected from the group consisting of an inducible promoter, or a constitutive promoter. 9. The method of claim 8, wherein the plasmid is injected into embryos in ovo. 10. The method of claim 8, wherein the plasmid is injected into chicks directly after hatching. 11. The method of claim 4, wherein first host cells are removed from the host; the vector is introduced into the host cells in vitro; host cells containing the vector are selected for; and the selected cells are then reintroduced into the host. 12. The method of claim 6, wherein the Ll ORF sequence in an antisense direction is incorporated into chicken germ line cells resulting in transgenic chickens. 13. A vaccine formulation comprising an immunologically effective amount of a 107 amino acid protein encoded by Ll ORF, or a peptide derived therefrom, wherein the protein consists essentially of the amino acid sequence Of SEQ ID No. 1. 14. The vaccine formulation according to claim 13, in which the protein was produced recombinantly from a host cell system genetically engineered to include an expression vector containing a nucleotide sequence consisting essentially of SEQ ID No. 1, said host cell is selected from the group consisting of bacteria, yeast, filamentous fungi, insect cell lines, and mammalian cell lines. 15. The vaccine formulation according to claim 13, in which the peptide is produced by chemical synthesis. 16. The vaccine formulation according to claim 13, further comprising a pharmaceutical carrier. 17. The vaccine according to claim 13, comprising a recombinant viral vector containing the Ll ORF under the control of a strong promoter so that the 107 amino acid protein is expressed from the vector. 18. The vaccine according to claim 17, wherein the viral vector is a live attenuated virus selected from the group consisting of infectious laryngotracheitis virus, chicken fowlpox virus, and herpesvirus of turkey. 19. A vaccine formulation comprising a recombinant unattenuated pathogenic non-oncogenic strain of MDV, wherein said strain is genetically engineered not to express the 107 amino acid protein of SEQ ID Nol. 1 by inserting a nucleotide sequence into the Ll ORF of SEQ ID No. 1 to interrupt expression from Ll ORF. 20. The vaccine formulation according to claim 19, wherein said recombinant MDV is a multivalent vaccine comprising one or more exogenous sequences inserted into the Ll ORF, and wherein said exogenous sequence encodes an antigen useful against a disease of poultry other than Marek's disease, said sequence is under the control of its own promoter or a MDV promoter. 21. The vaccine formulation according to claim 19, wherein the nucleotide sequence inserted into the Ll ORF comprises one or more genes endogenous to MDV and said gene encodes a major viral glycoprotein of MDV.

Inventors: O'CONNELL PRISCILLA H, OHASHI KAZUHIKO, SCHAT KAREL A, O'CONNELL, PRISCILLA, H., OHASHI, KAZUHIKO, SCHAT, KAREL, A.
Applicants: CORNELL RES FOUNDATION INC, CORNELL RESEARCH FOUNDATION, INC.
Application year: 1995
Main classification: C12N15
IPC codes: A61K31, A61K35, A61K38, A61K39, A61K48, A61P31, C07H21, C07K14, C12N15, C12R1